TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 848704

Group type: EXPERIMENTAL
Intervention: Premedication with atropine and diazepam after pre-operative starvation in hot weather
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-operative starvation in hot weather
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-operative starvation and premedication in temperate weather
Number of subjects: 0
Study: 31847821

Group type: EXPERIMENTAL
Intervention: Sit-stand desk intervention
Number of subjects: 15
Study: 28062087

Group type: EXPERIMENTAL
Intervention: SIB (Simultaneous Integrated Boost) of 46.8 or 49.95Gy
Number of subjects: 167

Group type: COMPARATOR
Intervention: SeB (Sequential Boost) of 10Gy in 4 fractions or 14.88Gy in 6 fractions
Number of subjects: 167
Study: 25516395

Group type: EXPERIMENTAL
Intervention: Cuffed nasal endotracheal tubes (RAE by Mallinckrodt)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncuffed nasal endotracheal tubes (nasal AGT NETT by Rüsch)
Number of subjects: 0
Study: 23460656

Group type: EXPERIMENTAL
Intervention: Extended cognitive‐behavioral treatment with 9 additional group sessions over a 14‐week period
Number of subjects: 141

Group type: COMPARATOR
Intervention: Nonextended treatment with 4 monthly smoking status calls
Number of subjects: 141
Study: 21560485

Group type: EXPERIMENTAL
Intervention: 6 puffs of salbutamol via the pMDI with Volumatic spacer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Easyhaler (DPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.15 mg/kg of salbutamol nebulized via oxygen (or compressed air)
Number of subjects: 0
Study: 19330241

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine (1:100,000)
Number of subjects: 59

Group type: COMPARATOR
Intervention: 2% plain lidocaine
Number of subjects: 59
Study: 17368253

Group type: COMPARATOR
Intervention: 5-mm non-shielded-bladed trocars (NSBTs)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 5-mm dilating-tip trocars (DTTs)
Number of subjects: 94
Study: 15716158

Group type: EXPERIMENTAL
Intervention: Studied pictures and corresponding auditory words
Number of subjects: 0

Group type: COMPARATOR
Intervention: Studied words only
Number of subjects: 0
Study: 11970797

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9449726

Group type: EXPERIMENTAL
Intervention: Patients with pneumothorax (50 patients, 6.9%)
Number of subjects: 725

Group type: COMPARATOR
Intervention: Patients without pneumothorax (675 patients, 93.1%)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Patients with any air leaks (77 patients, 10.6%)
Number of subjects: 725

Group type: COMPARATOR
Intervention: Patients without any air leaks (648 patients, 89.4%)
Number of subjects: 725
Study: 8732135

Group type: EXPERIMENTAL
Intervention: Fuchunpian with radiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiotherapy alone (Control)
Number of subjects: 60
Study: 2665304

Group type: EXPERIMENTAL
Intervention: Transthoracal injections of 0.5% solution of papain
Number of subjects: 109

Group type: COMPARATOR
Intervention: Active antiinflammatory therapy and bronchosanitation measures
Number of subjects: 109
Study: 811182

Group type: EXPERIMENTAL
Intervention: Group B: 1 to 15 meg of potassium acid phosphate per 1,000 K cal
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Group C: 15 to 25 meg of potassium acid phosphate per 1,000 K cal
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Group D: Greater than 25 meq of potassium acid phosphate per 1,000 K cal
Number of subjects: 19

Group type: COMPARATOR
Intervention: Group A: No phosphate additive
Number of subjects: 19
Study: 31435957

Group type: EXPERIMENTAL
Intervention: New powdered human milk fortifier
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control fortifier
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 153
Study: 31266245

Group type: EXPERIMENTAL
Intervention: TPSR program for 8 months
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study: 28483190

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment once per week for 10 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 25
Study: 26509984

Group type: EXPERIMENTAL
Intervention: Freeze-Dried Acellular Dermal Matrix (FDADM)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Solvent-Dehydrated Acellular Dermal Matrix (SDADM)
Number of subjects: 2
Study: 23028039

Group type: EXPERIMENTAL
Intervention: Extended letrozole (LET)
Number of subjects: 5166

Group type: COMPARATOR
Intervention: Switch from placebo (PLAC) to extended letrozole (LET)
Number of subjects: 5166
Study: 21196688

Group type: EXPERIMENTAL
Intervention: RN‐HSG with small Albures particles
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: RN‐HSG with large MAASOL particles
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: RN‐HSG during peri-ovulatory period
Number of subjects: 10
Study: 19493408

Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) plus Thymosin alpha1 (Talpha1)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 114
Study: 15588519

Group type: EXPERIMENTAL
Intervention: 1% N-acetylcarnosine (NAC) lubricant eye drops
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 137
Study: 10351466

Group type: EXPERIMENTAL
Intervention: Bi-annual, house-to-house re-treatment schedule free of charge using research project staff
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free re-treatment service via sentinel dipping stations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social marketing approach with cost-retrieval for net re-treatment services
Number of subjects: 0
Study: 7564436

Group type: EXPERIMENTAL
Intervention: External papaverine application (1.5 mg/ml)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Intraluminal papaverine application with heparinized blood (1.5 mg/ml) injected once
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Intraluminal papaverine application with heparinized blood (1.5 mg/ml) injected twice
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (submersion in papaverine solution only)
Number of subjects: 78
Study: 1979092

Group type: EXPERIMENTAL
Intervention: Hawksley random zero sphygmomanometer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UK Hawksley random zero sphygmomanometer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: US Hawksley random zero sphygmomanometer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard sphygmomanometers
Number of subjects: 0
Study: 6113993

Group type: EXPERIMENTAL
Intervention: 2.5 gm of 5% nonoxynol‐9 vaginal cream (Conceptrol) for 14 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: 2.5 gm of the cream base alone for 14 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 32
Study: 31543350

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment in BRVO
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment in CRVO
Number of subjects: 386
Study: 28590329

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir, darunavir, or raltegravir with tenofovir/emtricitabine backbone
Number of subjects: 235
Study: 25666002

Group type: EXPERIMENTAL
Intervention: Honey dressing after debridement
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no honey dressing)
Number of subjects: 72
Study: 25022125

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation combined with infusion of propofol (group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Simple propofol (group C)
Number of subjects: 90
Study: 20878849

Group type: EXPERIMENTAL
Intervention: Prescription sedative/hypnotics
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: OTC analgesics
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Any sleep aid
Number of subjects: 219
Study: 18720067

Group type: EXPERIMENTAL
Intervention: Combined surgical and corticosteroid treatment (oral prednisolone for 10 days, nasal budesonide for 1 month, followed by nasal steroids for 1 year)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Medical treatment alone (not specified in detail)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined surgical and corticosteroid treatment
Number of subjects: 32
Study: 17524620

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 40
Study: 15454647

Group type: EXPERIMENTAL
Intervention: Supportive care plus cisplatin-based chemotherapy (C)
Number of subjects: 725

Group type: COMPARATOR
Intervention: Supportive care alone (NoC)
Number of subjects: 725
Study: 11442535

Group type: EXPERIMENTAL
Intervention: Gasless laparoscopic cholecystectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy
Number of subjects: 50
Study: 9879412

Group type: EXPERIMENTAL
Intervention: Oral administration of 300 mg/day suplatast tosilate alone
Number of subjects: 83

Group type: COMPARATOR
Intervention: Immunotherapy using standardized D. farinae alone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Immunotherapy together with concurrent oral administration of 300 mg/day suplatast tosilate
Number of subjects: 83
Study: 7986713

Group type: EXPERIMENTAL
Intervention: Clodronate 2.4 g daily for 24 months
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo for 24 months
Number of subjects: 350
Study: 30198102

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg + tamsulosin 0.2 mg
Number of subjects: 607

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg
Number of subjects: 607
Study: 26651495

Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg daily for 7 days/month (two pulses for fingernails and three pulses for toenails)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Terbinafine 500 mg daily for 7 days/month (two pulses for fingernails and three pulses for toenails)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 90

Group type: COMPARATOR
Intervention: Terbinafine
Number of subjects: 90
Study: 26634453

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of botulinum toxin type A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study: 24184035

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine niosomal gel formulation (20mg in 20% w/v Pluronic F‐127 gel), applied once daily for 4 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16
Study: 20685528

Group type: EXPERIMENTAL
Intervention: Self-ligating bracket system (SmartClip)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional appliance (Victory)
Number of subjects: 66
Study: 19265345

Group type: COMPARATOR
Intervention: 3‐mL conventional syringe
Number of subjects: 320

Group type: COMPARATOR
Intervention: 10‐mL conventional syringe
Number of subjects: 320

Group type: COMPARATOR
Intervention: 3‐mL RPD
Number of subjects: 320

Group type: COMPARATOR
Intervention: 10‐mL RPD
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: 2-handed operation
Number of subjects: 320

Group type: COMPARATOR
Intervention: 1-handed operation
Number of subjects: 320
Study: 17313606

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 65
Study: 14969020

Group type: EXPERIMENTAL
Intervention: Aquacel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wet-to-dry gauze
Number of subjects: 50
Study: 11327191

Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 9497117

Group type: EXPERIMENTAL
Intervention: Non-invasive electrical stimulation, performed at home for one hour daily for a mean period of 45 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7514874

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enalapril (10 mg/d)
Number of subjects: 20
Study: 3074464

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg b.i.d.
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (160 mg trimethoprim + 800 mg sulphamethoxazole) b.i.d.
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 450
Study: 29769203

Group type: EXPERIMENTAL
Intervention: DPP-IV inhibitor alogliptin (early period up to 6 months)
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: DPP-IV inhibitor alogliptin (chronic period 6 months to end of follow-up)
Number of subjects: 5380

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 5380
Study: 27124177

Group type: EXPERIMENTAL
Intervention: Guided neoadjuvant chemotherapy (guided‐NACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional neoadjuvant chemotherapy (conventional‐NACT)
Number of subjects: 0
Study: 25703119

Group type: EXPERIMENTAL
Intervention: Contrast-induced acute kidney injury (CI-AKI) in stable CAD patients
Number of subjects: 1918

Group type: EXPERIMENTAL
Intervention: Contrast-induced acute kidney injury (CI-AKI) in ACS patients
Number of subjects: 1918

Group type: EXPERIMENTAL
Intervention: CI-AKI
Number of subjects: 1918

Group type: EXPERIMENTAL
Intervention: ΔSCr of 35%
Number of subjects: 1918
Study: 23645606

Group type: EXPERIMENTAL
Intervention: mobile CM (mCM)
Number of subjects: 22

Group type: COMPARATOR
Intervention: yoked control (noncontingent 4-week mCM)
Number of subjects: 22
Study: 19941691

Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle education including diet and physical activity over 7 months.
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 198
Study: 19700263

Group type: EXPERIMENTAL
Intervention: Mecamylamine (10mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16155272

Group type: EXPERIMENTAL
Intervention: Calcium supplement (450 mg)
Number of subjects: 27
Study: 12796524

Group type: EXPERIMENTAL
Intervention: Levodopa infusion
Number of subjects: 7
Study: 10494457

Group type: EXPERIMENTAL
Intervention: CI-988 100 mg TID for six weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 8888302

Group type: EXPERIMENTAL
Intervention: Shaded surfaces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Line-drawn surfaces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Textured surfaces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit surface boundaries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surface cues
Number of subjects: 0
Study: 1848169

Group type: EXPERIMENTAL
Intervention: L-arginine hydrochloride (0.5 g h-1 kg-1 body weight)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: L-lysine hydrochloride (0.44 g h-1 kg-1 body weight)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Baseline clearance of PGC
Number of subjects: 13

Group type: COMPARATOR
Intervention: PGA-5
Number of subjects: 13

Group type: COMPARATOR
Intervention: PGA-4
Number of subjects: 13

Group type: COMPARATOR
Intervention: PGA-3
Number of subjects: 13
Study: 6612181

Group type: EXPERIMENTAL
Intervention: Ornipressin 5 IU/10 mls lidocaine
Number of subjects: 127
Study: 31675538

Group type: EXPERIMENTAL
Intervention: Central European diet (CED)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MED)
Number of subjects: 144
Study: 29604599

Group type: EXPERIMENTAL
Intervention: Garlic extract (GE) 400 mg daily for 3 months
Number of subjects: 92
Study: 26887327

Group type: EXPERIMENTAL
Intervention: Exercise training (12 weeks of gym-based, personalized, and supervised exercise)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard care alone (control group)
Number of subjects: 13
Study: 25015436

Group type: COMPARATOR
Intervention: Valsartan/Amlodipine immediate release tablets (film-coated)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference brand product
Number of subjects: 0
Study: 22595826

Group type: EXPERIMENTAL
Intervention: Health Utilities Index Mark 3 (HUI3) score at 60 days
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: HUI3 ambulation, emotion, cognition, and pain attribute scores
Number of subjects: 439
Study: 19721013

Group type: EXPERIMENTAL
Intervention: Chronic blood transfusion with desferrioxamine chelation
Number of subjects: 271
Study: 17352516

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 or 200mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin as add-on therapy to metformin or pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin as add-on therapy to metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 0
Study: 15111779

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (1 mg/kg daily)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (7 mg/kg weekly)
Number of subjects: 79

Group type: COMPARATOR
Intervention: No iron supplementation (Control)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Weekly group
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Daily and control groups
Number of subjects: 79
Study: 11157138

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (15 days i.v. followed by 21 days oral)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Presence of leg ulcers
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Raised white cell count (WCC) at presentation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Development of abnormal renal function
Number of subjects: 75
Study: 9626844

Group type: EXPERIMENTAL
Intervention: Drug therapy with nitrates and atenolol or verapamil
Number of subjects: 70

Group type: COMPARATOR
Intervention: No treatment (untreated patients)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Drug therapy
Number of subjects: 70
Study: 7936821

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum inoculation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Human milk containing B. bifidum growth-promoting factor
Number of subjects: 31

Group type: COMPARATOR
Intervention: Formula milk without B. bifidum growth-promoting factor
Number of subjects: 31
Study: 3215887

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31453877

Group type: EXPERIMENTAL
Intervention: Intravenous propofol
Number of subjects: 313

Group type: COMPARATOR
Intervention: Volatile inhalational agents (desflurane or sevoflurane)
Number of subjects: 313
Study: 31547446

Group type: EXPERIMENTAL
Intervention: Twice the RDA (2RDA: 1.6 g protein/kg bodyweight/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Twice the RDA (2RDA)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Recommended dietary allowance (RDA: 0.8 g protein/kg bodyweight/day)
Number of subjects: 29
Study: 28544241

Group type: EXPERIMENTAL
Intervention: Single dose of 400 IU of RRR‐alpha‐tocopherol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of serum levels between treatment and control groups
Number of subjects: 50
Study: 26892694

Group type: EXPERIMENTAL
Intervention: Abdominal binder
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control
Number of subjects: 155
Study: 23899829

Group type: COMPARATOR
Intervention: Aerobic training-placebo (AT-PLA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Aerobic training-estrogen therapy (AT-ET)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sedentary-estrogen therapy (SED-ET)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sedentary-placebo (SED-PLA)
Number of subjects: 45
Study: 21853229

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVTA) 4 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pars plana vitrectomy (PPV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both IVTA and PPV
Number of subjects: 20
Study: 19651674

Group type: EXPERIMENTAL
Intervention: L-arginine (9 g/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Creatine (21 g/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: L-arginine plus creatine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17301040

Group type: EXPERIMENTAL
Intervention: Multicomponent nonpharmacological intervention (increased exposure to outdoor bright light, structured physical activity, bedtime routine, reduced nighttime noise and light)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 100
Study: 15133346

Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasonography (EBUS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluoroscopy only (Control)
Number of subjects: 50
Study: 11590377

Group type: EXPERIMENTAL
Intervention: Roflumilast (500 microg once daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 10211537

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400 mg on day 1, then 200 mg once daily for 9 days)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Clarithromycin (500 mg twice daily for 14 days)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 504

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 504
Study: 8545871

Group type: EXPERIMENTAL
Intervention: Neoral (NL)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sandimmune (SM)
Number of subjects: 9
Study: 2205289

Group type: EXPERIMENTAL
Intervention: Gestrinone 2.5 mg twice weekly
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 310164

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate with concomitant trisulfapyrimidines
Number of subjects: 90
Study: 31221208

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (IVR) intervention with age-appropriate procedural information.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care only (control group).
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (IVR) intervention.
Number of subjects: 200
Study: 29173736

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stimulant plus Parent Training (PT)
Number of subjects: 0